Sixia Chen

Dr. Sixia Chen

Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 May 2022 in Journal of Applied Statistics
Verified
Journal Article
Closed access
Sixia ChenSixia Chen
Sixia Chen
CXChao Xu
Chao Xu
High-dimensional data have been regarded as one of the most important types of big data in practice. It happens frequently in practice including genetic study, financial study, and geographical study. Missing data in high dimensional data analysis should be handled properly to reduce nonresponse bias. We discuss some modern machine learning techniques including penalized regression approaches, tree-based approaches, and deep learning (DL) for handling missing data with high dimensionality. Specifically, our proposed methods can be used for estimating general parameters of interest including population means and percentiles with imputation-based estimators, propensity score estimators, and doubly robust estimators. We compare those methods through some limited simulation studies and a real application. Both simulation studies and real application show the benefits of DL and XGboost approaches compared with other methods in terms of balancing bias and variance.

17 November 2020 in Journal of Survey Statistics and Methodology
Verified
Journal Article
Open access
PDF file
Sixia ChenSixia Chen
Sixia Chen
SYShu Yang
Shu Yang
JKJae Kwang Kim
Jae Kwang Kim
Data integration combining a probability sample with another nonprobability sample is an emerging area of research in survey sampling. We consider the case when the study variable of interest is measured only in the nonprobability sample, but comparable auxiliary information is available for both data sources. We consider mass imputation for the probability sample using the nonprobability data as the training set for imputation. The parametric mass imputation is sensitive to parametric model assumptions. To develop improved and robust methods, we consider nonparametric mass imputation for data integration. In particular, we consider kernel smoothing for a low-dimensional covariate and generalized additive models for a relatively high-dimensional covariate for imputation. Asymptotic theories and variance estimation are developed. Simulation studies and real applications show the benefits of our proposed methods over parametric counterparts.

17 March 2017 in Biometrika
Verified
Journal Article
Closed access
PDF file
Sixia ChenSixia Chen
Sixia Chen
DHDavid Haziza
David Haziza
Item nonresponse in surveys is often treated through some form of imputation. We introduce multiply robust imputation in finite population sampling. This is closely related to multiple robustness, which extends double robustness. In practice, multiple nonresponse models and multiple imputation models may be fitted, each involving different subsets of covariates and possibly different link functions. An imputation procedure is said to be multiply robust if the resulting estimator is consistent when all models but one are misspecified. A jackknife variance estimator is proposed and shown to be consistent. Random and fractional imputation procedures are discussed. A simulation study suggests that the proposed estimation procedures have low bias and high efficiency.


7 December 2018 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
SNSalman Nusrat
Salman Nusrat
TSTaseen Syed
Taseen Syed
SNSanober Nusrat
Sanober Nusrat
Sixia ChenSixia Chen
Sixia Chen
WCWei-Jen Chen
Wei-Jen Chen
KBKlaus Bielefeldt
Klaus Bielefeldt
Collaboration between health care professionals and the pharmaceutical industry often drives medical progress and, thus, benefits patients. Clinical trials reflect this reality, as industry sources support about half of the investigations focused on drugs or devices, raising concerns about potential conflicts of interest (COIs).1 Systematic reviews suggest an apparent bias of published studies that were more likely to report positive findings when the authors received support from industry.2,3 While journal editors responded to these findings by mandating disclosures of potential COIs,4-6 the possible extent of industry sponsorship came to light in the course of investigations by the Department of Justice, which led to a settlement between the United States and 5 companies owing to concerns about violations of federal anti-kickback regulations, as physicians had received consulting fees for using joint implants produced by these companies.7